Propel Bio Management
Latest statistics and disclosures from Propel Bio Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLT, PAGP, TCRX, MDGL, ACHV, and represent 59.86% of Propel Bio Management's stock portfolio.
- Added to shares of these 8 stocks: PAGP (+$26M), ABEO (+$5.3M), VRCA, ARDX, APLT, TSAT, Fidelity Inv Mmtrsy 1 680, Maat Pharma Saca.
- Started 4 new stock positions in ABEO, Maat Pharma Saca, PAGP, VRCA.
- Reduced shares in these 8 stocks: HIGH (-$27M), DAWN, MBB, MIRM, MRNS, STRO, XFOR, LQD.
- Sold out of its positions in DAWN, LQD, MBB, MRNS, MIRM, HIGH, STRO, XFOR.
- Propel Bio Management was a net buyer of stock by $94k.
- Propel Bio Management has $154M in assets under management (AUM), dropping by -9.87%.
- Central Index Key (CIK): 0001969764
Tip: Access up to 7 years of quarterly data
Positions held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 24 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Applied Therapeutics Comm (APLT) | 19.9 | $31M | +7% | 6.6M | 4.67 |
|
| Plains Gp Holdings Lp-cl Comm (PAGP) | 16.8 | $26M | NEW | 1.4M | 18.82 |
|
| Tscan Therapeutics Comm (TCRX) | 7.9 | $12M | 2.1M | 5.85 |
|
|
| Madrigal Pharmaceuticals Comm (MDGL) | 7.8 | $12M | 43k | 280.16 |
|
|
| Achieve Life Sciences Comm (ACHV) | 7.5 | $12M | 2.5M | 4.70 |
|
|
| Phathom Pharmaceuticals I Comm (PHAT) | 5.8 | $9.0M | 870k | 10.30 |
|
|
| Akero Therapeutics Comm (AKRO) | 5.0 | $7.7M | 328k | 23.46 |
|
|
| Avidity Biosciences Comm (RNA) | 4.7 | $7.3M | 179k | 40.85 |
|
|
| Ardelyx Comm (ARDX) | 4.4 | $6.9M | +55% | 925k | 7.41 |
|
| Abeona Therapeutics Comm (ABEO) | 3.4 | $5.3M | NEW | 1.2M | 4.24 |
|
| Fulcrum Therapeutics Comm (FULC) | 3.0 | $4.7M | 750k | 6.20 |
|
|
| Athira Pharma Comm (ATHA) | 2.6 | $4.0M | 1.5M | 2.65 |
|
|
| Telesat Corp Comm (TSAT) | 2.2 | $3.3M | +25% | 366k | 9.10 |
|
| Verrica Pharmaceuticals I Comm (VRCA) | 2.0 | $3.1M | NEW | 425k | 7.29 |
|
| Kura Oncology Comm (KURA) | 1.7 | $2.7M | 130k | 20.59 |
|
|
| Eiger Biopharmaceuticals Comm | 1.2 | $1.9M | 146k | 12.65 |
|
|
| Syndax Pharmaceuticals In Comm (SNDX) | 1.1 | $1.7M | 83k | 20.53 |
|
|
| Kymera Therapeutics Comm (KYMR) | 1.1 | $1.7M | 56k | 29.85 |
|
|
| Kayne Anderson Energy Inf Comm (KYN) | 1.0 | $1.5M | 147k | 10.33 |
|
|
| Trevi Therapeutics Comm (TRVI) | 0.5 | $775k | 260k | 2.98 |
|
|
| Fidelity Inv Mmtrsy 1 680 Comm | 0.2 | $317k | +49% | 317k | 1.00 |
|
| Cybin Comm (CYBN) | 0.1 | $230k | 850k | 0.27 |
|
|
| Maat Pharma Saca Comm | 0.0 | $9.8k | NEW | 1.4k | 7.16 |
|
| Chinook Therapeutics Comm | 0.0 | $9.8k | 79k | 0.12 |
|
Past Filings by Propel Bio Management
SEC 13F filings are viewable for Propel Bio Management going back to 2023
- Propel Bio Management 2024 Q2 filed Aug. 12, 2024
- Propel Bio Management 2024 Q1 filed May 13, 2024
- Propel Bio Management 2023 Q4 filed Feb. 14, 2024